文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Lipoprotein(a) Mass Levels Increase Significantly According to Genotype: An Analysis of 431 239 Patients.

作者信息

Moriarty Patrick M, Varvel Stephen A, Gordts Philip L S M, McConnell Joseph P, Tsimikas Sotirios

机构信息

From the Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City (P.M.M.); Salveo Diagnostics, Inc, Richmond, VA (S.A.V., J.P.M.); Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center (P.L.S.M.G.), Department of Medicine, Division of Endocrinology and Metabolism (P.L.S.M.G.), and Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center (S.T.), University of California San Diego, La Jolla.

出版信息

Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):580-588. doi: 10.1161/ATVBAHA.116.308704. Epub 2017 Jan 5.


DOI:10.1161/ATVBAHA.116.308704
PMID:28062489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5323356/
Abstract

OBJECTIVE: Lipoprotein(a) [Lp(a)] levels are genetically determined by hepatocyte apolipoprotein(a) synthesis, but catabolic pathways also influence circulating levels. genotypes have different affinities for the low-density lipoprotein (LDL) receptor and LDL-related protein-1, with ε2 having the weakest binding to LDL receptor at <2% relative to ε3 and ε4. APPROACH AND RESULTS: genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4), Lp(a) mass, directly measured Lp(a)-cholesterol levels, and a variety of apoB-related lipoproteins were measured in 431 239 patients. The prevalence of traits were ε2: 7.35%, ε3: 77.56%, and ε4: 15.09%. Mean (SD) Lp(a) levels were 65% higher in ε4/ε4 compared with ε2/ε2 genotypes and increased significantly according to genotype: ε2/ε2: 23.4 (29.2), ε2/ε3: 31.3 (38.0), ε2/ε4: 32.8 (38.5), ε3/ε3: 33.2 (39.1), ε3/ε4: 35.5 (41.6), and ε4/ε4: 38.5 (44.1) mg/dL (<0.0001). LDL-cholesterol, apoB, Lp(a)-cholesterol, LDL-cholesterol corrected for Lp(a)-cholesterol content, LDL-particle number, and small, dense LDL also had similar patterns. Patients with LDL-cholesterol ≥250 mg/dL, who are more likely to have LDL receptor mutations and reduced affinity for apoB, had higher Lp(a) levels across all apoE isoforms, but particularly in patients with ε2 alleles, compared with LDL <250 mg/dL. The lowest Lp(a) mass levels were present in patients with ε2 isoforms and lowest LDL-cholesterol. CONCLUSIONS: genotypes strongly influence Lp(a) and apoB-related lipoprotein levels. This suggests that differences in affinity of apoE proteins for lipoprotein clearance receptors may affect Lp(a) catabolism, suggesting a competition between Lp(a) and apoE protein for similar receptors.

摘要

相似文献

[1]
Lipoprotein(a) Mass Levels Increase Significantly According to Genotype: An Analysis of 431 239 Patients.

Arterioscler Thromb Vasc Biol. 2017-3

[2]
Relationship between Apolipoprotein E Genotype and Lipoprotein Profile in Patients with Coronary Heart Disease.

Molecules. 2022-2-18

[3]
Association of apolipoprotein E genotypes with lipid levels and coronary risk.

JAMA. 2007-9-19

[4]
The association of the apolipoprotein E gene promoter polymorphisms and haplotypes with serum lipid and lipoprotein concentrations.

Atherosclerosis. 2005-3

[5]
Low prevalence of lipid metabolism abnormalities in APOE ε2-genotype and male patients 60 years or older with schizophrenia.

BMC Psychiatry. 2017-12-12

[6]
Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals.

Int J Epidemiol. 2013-4

[7]
Apolipoprotein E gene polymorphisms are associated with carotid plaque formation but not with intima-media wall thickening: results from the Perth Carotid Ultrasound Disease Assessment Study (CUDAS).

Stroke. 2003-4

[8]
Comparative study of apolipoprotein-E polymorphism and plasma lipid levels in dyslipidemic and asymptomatic subjects, and their implication in cardio/cerebro-vascular disorders.

Neurochem Int. 2009-10-9

[9]
Human plasma lipid modulation in schistosomiasis mansoni depends on apolipoprotein E polymorphism.

PLoS One. 2014-7-22

[10]
Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.

Chin Med J (Engl). 2005-4-5

引用本文的文献

[1]
Lipoprotein(a) and cardiovascular disease.

Biochem J. 2024-10-2

[2]
Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease.

Atheroscler Plus. 2024-7-11

[3]
Association of Apolipoprotein E (APOE) Polymorphisms With Serological Lipid and Inflammatory Markers.

Cureus. 2024-5-20

[4]
Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling.

Clin Proteomics. 2024-3-1

[5]
Associations of Lipoprotein(a) Level with Cerebral Small Vessel Disease in Patients with Alzheimer's Disease.

Brain Sci. 2023-12-29

[6]
Gene-gene interaction detection with deep learning.

Commun Biol. 2022-11-12

[7]
Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia.

J Atheroscler Thromb. 2023-3-1

[8]
Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.

Front Genet. 2022-4-27

[9]
Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents.

Viruses. 2021-10-14

[10]
Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.

Vasc Health Risk Manag. 2021

本文引用的文献

[1]
PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

JACC Basic Transl Sci. 2016-10

[2]
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Lancet. 2016-9-21

[3]
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.

J Mol Med (Berl). 2016-7

[4]
Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).

J Clin Lipidol. 2016

[5]
Structure, function, and genetics of lipoprotein (a).

J Lipid Res. 2016-8

[6]
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases.

Cardiovasc Drugs Ther. 2016-2

[7]
Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis.

J Lipid Res. 2016-6

[8]
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

J Lipid Res. 2016-3

[9]
Apolipoprotein E Isoforms and AMD.

Adv Exp Med Biol. 2016

[10]
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.

J Am Coll Cardiol. 2015-9-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索